Effects of β-Blocker Therapy on High Sensitivity C-Reactive Protein, Oxidative Stress, and Cardiac Function in Patients With Congestive Heart Failure

Yuji Nagatomo, Tsutomu Yoshikawa, Takashi Kohno, Akihiro Yoshizawa, Toshihisa Anzai, Tomomi Meguro, Toru Satoh, Satoshi Ogawa

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: It is uncertain whether β-blocker therapy affects serum C-reactive protein (CRP) level in patients with congestive heart failure (CHF). We attempted to determine if β-blocker therapy decreases serum CRP production and to correlate the production with biomarkers and cardiac function in such patients. Methods and Results: Fifty-two patients with mild to moderate CHF with a left ventricular ejection fraction (EF) <40% were enrolled. They were randomly assigned to metoprolol or carvedilol treatment groups. The CRP concentration decreased significantly in patients with higher baseline CRP concentration, but not in those with lower baseline CRP concentrations. There was an inverse correlation between ΔCRP and ΔEF 16 weeks after the start of β-blocker therapy for patients with higher baseline CRP concentrations. In patients with higher baseline concentrations, CRP decreased in patients who received carvedilol, but not in those who received metoprolol. Plasma lipid peroxide (LPO) concentration significantly decreased, and there was an inverse correlation between ΔCRP and ΔLPO 16 weeks after the start of therapy. Conclusions: Administration of β-blockers is associated with attenuation of inflammatory marker in certain patients with CHF. The antioxidant effects of β-blockers, especially carvedilol, may play a role in mediating the phenomenon.

Original languageEnglish
Pages (from-to)365-371
Number of pages7
JournalJournal of Cardiac Failure
Volume13
Issue number5
DOIs
Publication statusPublished - 2007 Jun

Fingerprint

C-Reactive Protein
Oxidative Stress
Heart Failure
Metoprolol
Therapeutics
Lipid Peroxides
Blood Proteins
Stroke Volume
Antioxidants
Biomarkers
carvedilol

Keywords

  • cardiac function
  • inflammation
  • Interleukin-6
  • oxidative stress

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effects of β-Blocker Therapy on High Sensitivity C-Reactive Protein, Oxidative Stress, and Cardiac Function in Patients With Congestive Heart Failure. / Nagatomo, Yuji; Yoshikawa, Tsutomu; Kohno, Takashi; Yoshizawa, Akihiro; Anzai, Toshihisa; Meguro, Tomomi; Satoh, Toru; Ogawa, Satoshi.

In: Journal of Cardiac Failure, Vol. 13, No. 5, 06.2007, p. 365-371.

Research output: Contribution to journalArticle

Nagatomo, Yuji ; Yoshikawa, Tsutomu ; Kohno, Takashi ; Yoshizawa, Akihiro ; Anzai, Toshihisa ; Meguro, Tomomi ; Satoh, Toru ; Ogawa, Satoshi. / Effects of β-Blocker Therapy on High Sensitivity C-Reactive Protein, Oxidative Stress, and Cardiac Function in Patients With Congestive Heart Failure. In: Journal of Cardiac Failure. 2007 ; Vol. 13, No. 5. pp. 365-371.
@article{8d117719094743548ef5dc674d158fd2,
title = "Effects of β-Blocker Therapy on High Sensitivity C-Reactive Protein, Oxidative Stress, and Cardiac Function in Patients With Congestive Heart Failure",
abstract = "Background: It is uncertain whether β-blocker therapy affects serum C-reactive protein (CRP) level in patients with congestive heart failure (CHF). We attempted to determine if β-blocker therapy decreases serum CRP production and to correlate the production with biomarkers and cardiac function in such patients. Methods and Results: Fifty-two patients with mild to moderate CHF with a left ventricular ejection fraction (EF) <40{\%} were enrolled. They were randomly assigned to metoprolol or carvedilol treatment groups. The CRP concentration decreased significantly in patients with higher baseline CRP concentration, but not in those with lower baseline CRP concentrations. There was an inverse correlation between ΔCRP and ΔEF 16 weeks after the start of β-blocker therapy for patients with higher baseline CRP concentrations. In patients with higher baseline concentrations, CRP decreased in patients who received carvedilol, but not in those who received metoprolol. Plasma lipid peroxide (LPO) concentration significantly decreased, and there was an inverse correlation between ΔCRP and ΔLPO 16 weeks after the start of therapy. Conclusions: Administration of β-blockers is associated with attenuation of inflammatory marker in certain patients with CHF. The antioxidant effects of β-blockers, especially carvedilol, may play a role in mediating the phenomenon.",
keywords = "cardiac function, inflammation, Interleukin-6, oxidative stress",
author = "Yuji Nagatomo and Tsutomu Yoshikawa and Takashi Kohno and Akihiro Yoshizawa and Toshihisa Anzai and Tomomi Meguro and Toru Satoh and Satoshi Ogawa",
year = "2007",
month = "6",
doi = "10.1016/j.cardfail.2007.02.004",
language = "English",
volume = "13",
pages = "365--371",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "5",

}

TY - JOUR

T1 - Effects of β-Blocker Therapy on High Sensitivity C-Reactive Protein, Oxidative Stress, and Cardiac Function in Patients With Congestive Heart Failure

AU - Nagatomo, Yuji

AU - Yoshikawa, Tsutomu

AU - Kohno, Takashi

AU - Yoshizawa, Akihiro

AU - Anzai, Toshihisa

AU - Meguro, Tomomi

AU - Satoh, Toru

AU - Ogawa, Satoshi

PY - 2007/6

Y1 - 2007/6

N2 - Background: It is uncertain whether β-blocker therapy affects serum C-reactive protein (CRP) level in patients with congestive heart failure (CHF). We attempted to determine if β-blocker therapy decreases serum CRP production and to correlate the production with biomarkers and cardiac function in such patients. Methods and Results: Fifty-two patients with mild to moderate CHF with a left ventricular ejection fraction (EF) <40% were enrolled. They were randomly assigned to metoprolol or carvedilol treatment groups. The CRP concentration decreased significantly in patients with higher baseline CRP concentration, but not in those with lower baseline CRP concentrations. There was an inverse correlation between ΔCRP and ΔEF 16 weeks after the start of β-blocker therapy for patients with higher baseline CRP concentrations. In patients with higher baseline concentrations, CRP decreased in patients who received carvedilol, but not in those who received metoprolol. Plasma lipid peroxide (LPO) concentration significantly decreased, and there was an inverse correlation between ΔCRP and ΔLPO 16 weeks after the start of therapy. Conclusions: Administration of β-blockers is associated with attenuation of inflammatory marker in certain patients with CHF. The antioxidant effects of β-blockers, especially carvedilol, may play a role in mediating the phenomenon.

AB - Background: It is uncertain whether β-blocker therapy affects serum C-reactive protein (CRP) level in patients with congestive heart failure (CHF). We attempted to determine if β-blocker therapy decreases serum CRP production and to correlate the production with biomarkers and cardiac function in such patients. Methods and Results: Fifty-two patients with mild to moderate CHF with a left ventricular ejection fraction (EF) <40% were enrolled. They were randomly assigned to metoprolol or carvedilol treatment groups. The CRP concentration decreased significantly in patients with higher baseline CRP concentration, but not in those with lower baseline CRP concentrations. There was an inverse correlation between ΔCRP and ΔEF 16 weeks after the start of β-blocker therapy for patients with higher baseline CRP concentrations. In patients with higher baseline concentrations, CRP decreased in patients who received carvedilol, but not in those who received metoprolol. Plasma lipid peroxide (LPO) concentration significantly decreased, and there was an inverse correlation between ΔCRP and ΔLPO 16 weeks after the start of therapy. Conclusions: Administration of β-blockers is associated with attenuation of inflammatory marker in certain patients with CHF. The antioxidant effects of β-blockers, especially carvedilol, may play a role in mediating the phenomenon.

KW - cardiac function

KW - inflammation

KW - Interleukin-6

KW - oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=34250804754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250804754&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2007.02.004

DO - 10.1016/j.cardfail.2007.02.004

M3 - Article

VL - 13

SP - 365

EP - 371

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 5

ER -